OncLive TV

Wen Wee Ma, MBBS, discusses first-line treatment considerations in metastatic pancreatic cancer.

Yung Lyou, MD, PhD, discusses emerging biomarkers in prostate cancer.

Betsy O'Donnell, MD, discusses the promise of novel targets in multiple myeloma.

Sajeve Samuel Thomas, MD, discusses the safety profile of lifileucel plus pembrolizumab in advanced melanoma.

Sara M. Tolaney, MD, MPH, discusses tailoring HER2-directed therapies in the treatment of patients with breast cancer. 

Dana Chase, MD, FACOG, discusses the importance of utilizing genetic testing to guide treatment decisions for patients with ovarian cancer.

Hiromichi Shirasu, MD, discusses the design of the GALAXY trial, part of the CIRCULATE-Japan project, which is examining circulating tumor DNA in patients with resectable colorectal cancer.

Daniel Pollyea, MD, MS, discusses indications for anti-CD33 therapy in the treatment of patients with acute myeloid leukemia.

Ehab L. Atallah, MD, discusses the clinical implications of the phase 3 QUAZAR AML-001 trial in acute myeloid leukemia.

Mitchell R. Smith, MD, PhD, discusses the rationale for the phase 2 ECOG-ACRIN E1411 trial in mantle cell lymphoma.

Yung Lyou, MD, PhD, discusses optimal sequencing with apalutamide in prostate cancer.

Paul M. Barr, MD, discusses the clinical implications of the long-term results of the phase 3 RESONATE-2 trial in chronic lymphocytic leukemia.

Peter Martin, MD, discusses the role of maintenance therapy with rituximab in mantle cell lymphoma.

Omar Nadeem, MD, discusses the uptake of novel therapies in heavily pretreated multiple myeloma.

Adam Sperling, MD, PhD, discusses future research with CAR T-cell therapy in multiple myeloma.

Leanne Burnham, PhD, discusses health disparities in prostate cancer.

David M. O'Malley, MD, discusses the promise of antibody-drug conjugates in ovarian cancer.

Evangelia Sereti, MSc, PhD, discusses the unmet need addressed with the addition of NOV202 to olaparib in BRCA1/2-mutated prostate cancer.

Eirwen M. Miller, MD, discusses the safety and efficacy of veliparib vs other PARP inhibitors used in the treatment of patients with ovarian cancer.

Scott Tagawa, MD, MS, FACP, discuses the benefits of radium-223 dichloride in prostate cancer.

Jing-Yi Chern, MD, ScM, discusses outcomes with PARP inhibitors in patients with recurrent ovarian cancer.

Robert Dreicer, MD, discusses the initial findings with sabizabulin in metastatic castration-resistant prostate cancer.

Paolo Ghia, MD, PhD, discusses the clinical implications of the phase 2 CAPTIVATE trial in chronic lymphocytic leukemia.

Shaji K. Kumar, MD, discusses the integration of CAR T-cell therapy into the treatment paradigm for heavily pretreated multiple myeloma.

Daniel Pollyea, MD, MS, discusses improving induction outcomes for newly diagnosed patients with acute myeloid leukemia.

David Sallman, MD, discusses unmet needs in the treatment of patients with higher-risk myelodysplastic syndromes.

Michael R. Grunwald, MD, FACP, discusses the clinical implications of tisagenlecleucel in the treatment of patients with B-cell acute lymphoblastic leukemia.

Vinayak G. Wagaskar, MBBS, discusses potential explanations for a paradoxical relationship between obesity and outcomes observed in prostate cancer.

Evangelia Sereti, MSc, PhD, discusses the next steps with the combination of NOV202 and olaparib in BRCA1/2-mutated prostate cancer.

Jeremy C. Jones, MD, discusses the risk of interstitial lung disease with fam-trastuzumab deruxtecan-nxki in colorectal cancer.